biotech · Blepharitis · Meibomian Gland Dysfunction · TARS
Tarsus Pharmaceuticals
Tarsus Pharmaceuticals clinical programs — 14 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 15440 Laguna Canyon Rd, Irvine, California 92618, US
- Founded
- 2017
- Employees
- 403
- Programs
- 14
- Drugs
- 10
- Patents
- 9
Tarsus Pharmaceuticals projects
14 ClinicalTrials.gov programs sponsored by Tarsus Pharmaceuticals.
Tarsus Pharmaceuticals has 14 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
TP-03
Tarsus Pharmaceuticals
Blepharitis
1 trial -
TP-03, 0.25%
Tarsus Pharmaceuticals
Blepharitis
1 trial -
Lotilaner Gel, 2.0%
Tarsus Pharmaceuticals
Papulopustular Rosacea
1 trial -
Low Dose TP-05
Tarsus Pharmaceuticals
Healthy Volunteer
1 trial -
TP-03
Tarsus Pharmaceuticals
Meibomian Gland Dysfunction
1 trial -
TP-05 (lotilaner) Low Dose
Tarsus Pharmaceuticals
Lyme Disease
1 trial -
Vehicle of TP-03
Tarsus Pharmaceuticals
Meibomian Gland Dysfunction
1 trial -
lotilaner
Tarsus Pharmaceuticals
Ocular Rosacea
1 trial -
TP-03 (Lotilaner Ophthalmic Solution), 0.25%
Tarsus Pharmaceuticals
Healthy
1 trial -
TP-05 (lotilaner oral capsules)
Tarsus Pharmaceuticals
Healthy
1 trial -
TP-05 (lotilaner oral), fasted group
Tarsus Pharmaceuticals
Healthy
1 trial -
Lotilaner ophthalmic solution, 0.25%
Tarsus Pharmaceuticals
Demodex Blepharitis
1 trial -
Standart medical treatment
Tarsus Pharmaceuticals
High Intensity Interval Training
1 trial -
Uteratonic administration
Tarsus Pharmaceuticals
Placenta Abruptio
1 trial
Frequently asked questions
How many clinical projects does Tarsus Pharmaceuticals have?
14 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.